Clik here to view.
全球首批患者接受Edison®新型组织切片系统治疗
美国明尼阿波利斯 (美国商业资讯)– 无创型 Edison® 组织摧毁术系统制造商 HistoSonics (www.histosonics.com)今天宣布，在近期获得FDA De Novo批准后，罗彻斯特大学医学中心的一名患者接受了全球首例使用Edison系统的靶向肝肿瘤治疗。在同一周，克利夫兰诊所(Cleveland...
View ArticleClik here to view.
Clik here to view.
百奥赛图与Radiance Biopharma达成双抗ADC协议
中国北京与美国波士顿 (美国商业资讯)– 百奥赛图（北京）医药科技股份有限公司（“百奥赛图”，股票代码02315.HK），一家创新技术驱动新药研发的国际性生物技术公司，今日宣布与Radiance Biopharma Inc.（“Radiance”），一家专注于开发下一代抗体偶联药物的生物技术公司，达成一项独家选择与授权协议。...
View ArticleClik here to view.
Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with...
BEIJING & BOSTON Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces...
View ArticleClik here to view.
HighField Biopharmaceuticals HF1K16 Phase 1a Data Suggests the New...
HANGZHOU, China HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced today it has completed its Phase 1a study of HF1K16....
View ArticleClik here to view.
Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with...
BEIJING & BOSTON Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen,” HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces...
View ArticleClik here to view.
バイオサイトジェン、Radiance Biopharmaとバイスペシフィック抗体薬物複合体に関する契約に署名
北京&ボストン （ビジネスワイヤ） — 新しい抗体治療法の発見に焦点を当てたグローバルなバイオテクノロジー企業であるバイオサイトジェン・ファーマシューティカルズ（北京）（以下、「バイオサイトジェン」、HKEX：02315）は、次世代の抗体薬物複合体を開発するバイオテクノロジー企業であるRadiance Biopharma...
View ArticleClik here to view.
Zai Lab Announces The New England Journal of Medicine Publication...
SHANGHAI & CAMBRIDGE, Mass. Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced The New England Journal of Medicine (NEJM) has published data from the registrational Phase 1/2 TRIDENT-1...
View ArticleClik here to view.
Canon Medical Systems and Olympus Announce Business Alliance regarding...
TOKYO Canon Medical Systems Corporation (Canon Medical) and Olympus Corporation (Olympus), today announced that we have reached an agreement to collaborate on Endoscopic Ultrasound Systems. Canon...
View ArticleClik here to view.
InnoCare Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a commercial-stage biotech company, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug...
View ArticleClik here to view.
ICPO Foundation Partners With Leading Pharmaceutical Company to Fund 130...
WIESBADEN, Germany Today, the Academy for Theranostics, a transformative initiative developed by the International Centers for Precision Oncology (ICPO) Foundation, announced that ADACAP (Advanced...
View ArticleClik here to view.
Takeda Named Global Top Employer for Seventh Consecutive Year
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced that for the seventh consecutive year, it has received global Top Employer® certification for 2024. Takeda is one of...
View ArticleClik here to view.
Takeda连续第七年被评为全球杰出雇主
日本大阪和马萨诸塞州坎布里奇 (美国商业资讯)– Takeda ( TSE:4502/NYSE:TAK )今天宣布，该公司已获得2024年全球杰出雇主(Top Employer®)认证，从而连续七年获此殊荣。Takeda是仅有的17家获得全球认可的公司之一，此外还在24个国家获得了杰出雇主认证。 杰出雇主调研机构计划根据人力资源最佳实践调查(HR Best Practices...
View ArticleClik here to view.
武田薬品工業、7年連続でトップ・エンプロイヤーに認定
大阪、米マサチューセッツ州ケンブリッジ （ビジネスワイヤ） — 武田薬品 （ TSE：4502/NYSE：TAK ） は、7年連続で世界的な2024年トップ・エンプロイヤー（Top Employer®）認証を受けたことを発表しました。武田薬品は、世界的な評価を受けたわずか17社のうちの1社であり、24か国でトップ・エンプロイヤーとして認定されました。...
View ArticleClik here to view.
Fujirebio与Agappe就CLIA免疫分析领域的业务合作达成协议
东京和印度科钦 (美国商业资讯)– Fujirebio Holdings, Inc.和Agappe Diagnostics Ltd今日宣布，双方已就面向免疫学设备Mispa i60和Mispa...
View ArticleClik here to view.
Fujirebio and Agappe Enter into an Agreement on Business Collaboration in the...
TOKYO & COCHIN, India Fujirebio Holdings, Inc. and Agappe Diagnostics Ltd today announced that they have entered into an agreement of Contract Development and Manufacturing Organization (CDMO)...
View ArticleClik here to view.
InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first pediatric patient...
View ArticleClik here to view.
冠科生物全球肿瘤研究实验室取得ISO与CAP认证
美国圣地亚哥 (美国商业资讯)– 冠科生物是一家全球合同研究组织（CRO），为JSR Life Sciences旗下子公司。该公司自豪地宣布其全球实验室设施已成功通过了一系列年度ISO现场审计，并取得了零差异的完美记录。 ISO标准涵括了以下几点： ISO 9001 质量管理 ISO 14001 环境管理 ISO 45001 职业健康与安全管理体系 ISO 20000 IT服务管理 ISO...
View ArticleClik here to view.
Crown Bioscienceのグローバルがん研究施設が権威あるISOおよびCAP認証を取得
米国サンディエゴ （ビジネスワイヤ） — 世界的な医薬品開発業務受託機関（CRO）であり、JSRライフサイエンスの子会社であるCrown Bioscienceは、同社の世界的なラボ施設が一連の年次ISOオンサイト監査に合格し、不一致ゼロの完璧な成果を成し遂げたことを発表します。 認証されたISO規格は以下の通りです。 ISO 9001 品質マネジメント ISO14001環境マネジメント ISO...
View ArticleClik here to view.
Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully...
BEIJING Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced the launch of a new sub-brand, RenBiologics™, to represent the company’s antibody discovery...
View Article